亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Evolution of low HER2 expression between early and advanced-stage breast cancer

免疫组织化学 医学 乳腺癌 肿瘤科 生物标志物 内科学 阶段(地层学) 人表皮生长因子受体2 活检 激素受体 癌症 曲妥珠单抗 人口 病理 生物 古生物学 环境卫生 生物化学
作者
Paolo Tarantino,Sara Gandini,Eleonora Nicolò,Pamela Trillo,Federica Giugliano,Paola Zagami,Grazia Vivanet,Federica Bellerba,Dario Trapani,Antonio Marra,Angela Espósito,Carmen Criscitiello,Giuseppe Viale,Giuseppe Curigliano
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:163: 35-43 被引量:205
标识
DOI:10.1016/j.ejca.2021.12.022
摘要

Low human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this biomarker during the course of disease is still poorly characterised, and controversial data exist on its prognostic implications.We reviewed data of patients with HER2-negative BC according to the latest ASCO/CAP guidelines referred between January 2014 and December 2020. We grouped patients based on the immunohistochemistry (IHC) expression of HER2, HER2-zero (IHC 0) and HER2-low subgroup (IHC 1+ or 2+/ISH-negative) and evaluated the evolution of HER2 expression between the primary tumour and the first biopsy collected in the advanced setting. Disease-free survival, overall survival and progression-free survival were compared between patients with HER2-zero and HER2-low expression on the primary tumour.232 patients were included in the analysis. Among the overall population, there was a relevant discordance in HER2 expression between the primary tumour and the matched biopsy (K = 0.33, 95%CI 0.21-0.44): 44% of the HER2-zero primary tumour showed an increased HER2 score on biopsy, and 22% of the HER2-low primary tumours turned into HER2-IHC 0. The findings in the sub-populations of hormone-receptors positive (K = 0.32, 95%CI 0.19-0.45) and triple-negative tumours (K = 0.18, 95%CI -0.09-0.46) were consistent with the primary analysis. No difference in survival outcomes was observed between HER2-low and HER2-zero primary tumours.HER2-low expression is dynamic in BC and may be enriched in the advanced-stage setting. No prognostic significance was demonstrated for HER2-low expression.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
parantal发布了新的文献求助10
刚刚
kunkun完成签到 ,获得积分20
2秒前
ding的应助被施囧采纳,获得10
5秒前
Lightning123完成签到,获得积分10
6秒前
疯狂的山楂完成签到,获得积分10
7秒前
9秒前
卷卷完成签到 ,获得积分10
11秒前
大模型的应助被困困困困昕采纳,获得10
12秒前
Saturday完成签到,获得积分10
15秒前
施囧发布了新的文献求助10
15秒前
爱笑歌曲完成签到,获得积分10
16秒前
苗条的采梦完成签到,获得积分10
18秒前
CodeCraft的应助被科研通管家采纳,获得10
18秒前
奔跑的应助被科研通管家采纳,获得10
18秒前
null的应助被科研通管家采纳,获得10
19秒前
桐桐的应助被科研通管家采纳,获得10
19秒前
19秒前
21秒前
Yoooo完成签到 ,获得积分10
21秒前
22秒前
gxyqqb完成签到,获得积分20
22秒前
24秒前
李健的粉丝团团长的应助被15采纳,获得10
26秒前
白华苍松发布了新的文献求助10
26秒前
星辰大海的应助被fff采纳,获得10
27秒前
chiaoyin999发布了新的文献求助10
27秒前
Akim的应助被美满惜雪采纳,获得10
30秒前
斯文败类的应助被独特石头采纳,获得10
34秒前
che发布了新的文献求助10
37秒前
39秒前
美满惜雪发布了新的文献求助10
42秒前
冰冰完成签到 ,获得积分10
43秒前
Lee完成签到,获得积分20
44秒前
47秒前
48秒前
秋风的应助被美满惜雪采纳,获得10
49秒前
活力傲柏完成签到,获得积分10
51秒前
52秒前
58秒前
过客完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184964
求助须知:如何正确求助?哪些是违规求助? 9573917
关于积分的说明 21833687
捐赠科研通 7782425
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161